Pharmalink AB, a specialty pharma company focused on orphan and niche products, today announces its product Busulipoa , a best-in-class conditioning agent for use in cancer patients prior to hematopoietic stem cell transplantation , has received orphan drug designation from the US Food and Drug Administration .
http://www.sys-con.com/node/2852352
http://www.sys-con.com/node/2852352
No comments:
Post a Comment